Day: July 19, 2021

Marathon Digital Holdings Reminds Shareholders To Vote at the Upcoming 2021 Annual Meeting of Shareholders LAS VEGAS, July 19, 2021 (GLOBE NEWSWIRE) — Marathon Digital Holdings, Inc. (NASDAQ:MARA) (“Marathon” or “Company”), one of the largest enterprise Bitcoin mining companies in North America, today announced that leading independent proxy advisory firm Institutional Shareholder Services Inc. (“ISS”) has expressed its support for all upcoming agenda items at Marathon’s 2021 Annual Meeting of shareholders (the “Annual Meeting”), which will be held on Friday, August 6, 2021. In addition to the support expressed by ISS, the board of directors of the Company unanimously recommends a vote “FOR” approval of all proposals. Marathon’s 2021 Annual Meeting is to be held at the Wynn Las Vegas, 3131 Las Vegas Blvd...

TAMPA, Fla., July 19, 2021 (GLOBE NEWSWIRE) — First Citrus Bancorporation, Inc. (OTC Markets: FCIT), the parent bank holding company for First Citrus Bank, released its financial results for the second quarter of 2021. Net earnings of $1,960,000 for the quarter ended June 30, 2021, was the highest in company history. During the second quarter, assets, deposits, and non-Paycheck Protection Program (“PPP”) loans also grew to record levels. Second Quarter 2021 Highlights (compared to second quarter 2020)Net earnings growth of 52%; Asset growth of 14%; Non-PPP loan growth of 12%; Demand deposit growth of 41%; Deposit growth of 20%; Earnings per share growth of 51%.Net earnings for the quarter ended June 30, 2021, was $1,960,000 or $0.95 per share, compared to the net income of $1,290,000, or $0.63 per share for the...

DNA PLC STOCK EXCHANGE RELEASE 19 JULY 2021, 15:00 EEST Vilhelmiina Wahlbeck, SVP, Communications, Sustainability and Brand Development at DNA, has been appointed as member of DNA’s Executive Team. Vilhelmiina Wahlbeck, 44, has worked in the telecommunications industry for most of her career, first in Telia’s Finnish subsidiary, then as Head of Communications at DNA’s previous parent company Finnet Oy and since 2007 as VP, Corporate Communications at the current DNA Group. Since 2016, she has also been responsible for DNA’s corporate responsibility, and since the beginning of this year, her job description expanded to include DNA’s brand development. Vilhelmiina Wahlbeck holds a master’s degree in political science. She reports to DNA’s CEO. “Both corporate responsibility and brands that stand out are...

Deal strengthens BioNTech’s cell therapy pipeline by accelerating individualized solid tumor Neoantigen TCR cell therapy research and development program and adding manufacturing footprint in North America Kite remains focused on rapid advancement of current CAR T-Cell therapies to reach more patients and further optimize therapeutic potential of cell therapy Transaction expected to close by end of July 2021 MAINZ, Germany & Santa Monica, USA, July 19, 2021 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) und Kite, a Gilead Company (Nasdaq: GILD, “Kite”) today announced the two companies have entered into a purchase agreement for BioNTech to acquire Kite’s solid tumor neoantigen T cell receptor (TCR) R&D platform and clinical manufacturing facility in Gaithersburg, MD. The acquired Gaithersburg facility will provide production capacity...

DNA PLC STOCK EXCHANGE RELEASE 19 JULY 2021, 15:00 EEST Ville Virtanen, BEng, EMBA, has been named DNA Plc’s Chief Technology Officer (CTO) and a member of the Executive Team. Ville Virtanen, 45, will start in his new position on 1 September 2021. He is taking up the post after acting as the VP of DNA’s Core and IP Networks department. Virtanen has been at DNA since 2003 and has been broadly responsible for the services of DNA’s mobile and fixed networks, as well as its business-critical service platforms. Before joining DNA, Ville held a number of positions related to the development of networks and IT services at Telia. In his new role, Virtanen will be responsible for DNA’s various network technologies and their development. He reports to the CEO of DNA. Virtanen succeeds Tommy Olenius, who will be continuing in the position until the...

YONKERS, N.Y., July 19, 2021 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced multiple presentations, including two oral presentations, of data from its portfolio of DLAs from the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), now available online. “The data presented at ECCMID further illustrates the potential utility of our lysin therapeutic modalities to address important unmet medical needs. Our new in vitro data suggests that our lead lysin, exebacase, currently in Phase 3 with Breakthrough therapy designation for...